Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas by Freihoff, D et al.
Breast carcinoma represents the most common malignancy of
women in Western countries. Despite its prevalence, the molecular
mechanisms of breast cancer formation and progression are still
poorly understood. Molecular studies suggest that tumour-
suppressor genes involved in hereditary tumour formation may
also be altered in their sporadic counterparts (Fearon, 1997). Five
per cent of all patients with breast carcinomas report a family
history and the majority of these familial cases have been associ-
ated with germline mutations of the BRCA1 or BRCA2 tumour-
suppressor genes (Miki et al, 1994; Wooster et al, 1995). However,
the BRCA1 and BRCA2 genes are not usually altered in sporadic
breast carcinomas (Lancaster et al, 1996; Miki et al, 1996),
although loss of heterozygosity (LOH) in the BRCA1 and BRCA2
on chromosomal arms 17q and 13q is frequently observed
(Schmutzler et al, 1997).
Recently, the PTEN/MMAC1/TEP1 tumour-suppressor gene has
been identified on chromosomal band 10q23.3 (Li and Sun, 1997;
Li et al, 1997; Steck et al, 1997). The product of this gene harbours
a tyrosine phosphatase domain which shares high sequence
homology with the cytoskeleton proteins tensin and auxilin.
Mutations of PTEN were observed in a variety of tumours
including breast carcinoma cell lines and primary invasive breast
carcinomas (Li et al, 1997; Steck et al, 1997). These mutations
included homozygous deletions and frameshift or nonsense muta-
tions. Moreover, loss of heterozygosity affecting 10q23.3 was
detected in as many as 50% of primary breast carcinomas.
Germline mutations of PTEN have been identified in Cowden
disease, a rare autosomal dominant cancer syndrome characterized
by malignancies of the breast, thyroid and brain (Liaw et al, 1997).
These observations point to PTEN as an interesting candidate for a
tumour-suppressor gene associated with breast cancer.
Recent studies on sporadic tumours demonstrated that muta-
tions in the PTEN gene are frequent events in glioblastomas,
malignant melanomas and endometrial carcinomas of the
endometrioid type (Guldberg et al, 1997; Kong et al, 1997;
Rasheed et al, 1997; Tashiro et al, 1997; Wang et al, 1997). In
endometrial carcinomas, PTEN mutations were predominantly
found in tumours with microsatellite instability (Kong et al, 1997;
Tashiro et al, 1997). It remains to be shown whether the associa-
tion of PTEN mutations and microsatellite instability is of biolog-
ical significance. In a series of 54 sporadic breast carcinomas, two
deletions resulting in truncated proteins and various missense
mutations of unknown significance have been reported (Rhei et al,
1997). To further elucidate the potential role of PTEN in breast
carcinomas, we analysed 103 sporadic breast carcinomas for muta-
tions, homozygous deletions and loss of heterozygosity, and 25
families with hereditary breast cancer for constitutive mutations in
the PTEN gene.
MATERIALS AND METHODS
Tumour specimens from sporadic breast carcinomas
and blood samples from patients with hereditary breast
carcinomas
Breast cancer families were recruited at the University Hospital
Bonn and the Department of Medical Genetics, University of
Munich, Germany. Our series comprised 25 families fulfilling the
following criteria: (1) at least two affected female relatives with
breast or ovarian cancer and at least one patient with age at mani-
festation of less than 50 years; (2) one affected female with two
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cancers, either bilateral breast cancer or breast and ovarian cancer;
(3) one affected female with an age of onset for breast cancer
under 35 years. Male breast cancer did not occur in these families.
Most of the families were high-risk families with at least three
breast or ovarian carcinomas (Table 1). BRCA1 mutations were
excluded in all families by complete sequencing of the coding
region including exon/intron boundaries. BRCA2 mutation
analysis is currently under investigation and so far excluded by
single-strand conformation polymorphism (SSCP) analysis in five
families. In addition, in ten families frequent mutations in the
BRCA2 gene could be excluded by direct sequencing of exons 9,
23 and 27.
Tissue was obtained from 103 women undergoing surgery for
sporadic breast carcinomas at the University Hospital Bonn, the St.
Elisabeth Hospital Bonn-Bad Godesberg and the Marienhospital
Bruehl, Germany. Malignant tumours were grouped according to
the UICC TNM (Spiessl et al, 1990) classification. The WHO clas-
sification was used for histopathological analysis (World Health
Organization, 1981). Histological grading was performed
according to Bloom and Richardson (1957). The oestrogen and
progesterone receptor (ER and PR) status were determined by the
dextran-coated charcoal (DCC) method or by a monoclonal anti-
body assay (Remmele et al, 1986). Thirteen of the carcinomas
represented recurrent or metastatic tumours, 88 primary carci-
nomas, and from two no data were available. Among the primary
carcinomas, 36 corresponded to pT1 and 40 were larger tumours
(pT > 1). From 12 tumours, no data were available. Forty-nine
tumours were classified as pN0, 38 were characterized by lymph
node infiltration, and from one tumour no staging data was avail-
able. Sixty-seven carcinomas were histopathologically classified as
ductal carcinomas, nine as lobular carcinoma, two as medullary
carcinoma, two as mucinous carcinomas, one as tubular carcinoma
and three as ductal carcinoma in situ. From four tumours, no histo-
logical subclassification was obtained. Twenty-four carcinomas
were classified as grade III, 59 tumours as grade II or I, and from
five tumours grading was not available. Seventeen tumours were
ER negative and 66 ER positive. PR expression was detected in 50
tumours and undetectable in 33 tumours. For five carcinomas, the
hormone receptor status was not available.
Tissue samples were stored at –80°C and blood samples at
–20°C until further treatment. Tumour tissue was processed by
microdissection to exclude regions of normal breast tissue and
only samples containing more than 90% tumour cells were investi-
gated. DNA was extracted from tissue and peripheral leucocytes
using a conventional phenol–chloroform protocol.
SSCP analysis and DNA sequencing
For a mutational analysis of the PTEN gene, intronic and overlap-
ping exonic primers were used for amplification (Duerr et al,
1998). The primers cover the entire coding sequence as well as the
exon/intron boundaries of the PTEN gene. Polymerase chain reac-
tion (PCR) was performed in a volume of 10 ml containing 20 ng
of DNA, 50 mM potassium chloride, 10 mM tris-HCl, 200 mM of
each dNTP, 0.1% gelatin, 10 pmol of each primer, 1.0–2.0 mM
magnesium chloride and 0.25 U Taq polymerase. Initial denatura-
tion at 94°C for 3 min was followed by 30 cycles on an automated
thermal cycler (Hybaid, Omnigene, USA). Denaturation at 94°C
for 30 s was followed by annealing at 50–55°C for 40 s and exten-
sion at 72°C for 40 s. A final extension step at 72°C for 10 min
was added. Single-strand conformation polymorphism (SSCP)
analysis was carried out on a sequencing apparatus (Pokerface II,
A
B
T1 B1 T2 B2
TGATCTTGACAAAGCAAAGCCAACCGA
60 70 80
10 bp deletion
Figure 1 Somatic PTEN mutation in one breast carcinoma. (A) The silver-
stained SSCP gel shows an aberrant migration pattern of the amplified
tumour DNA sample T2 (T, tumour) in comparison with the corresponding
blood sample B2 (B, blood). (B) Sequence analysis of the tumour DNA
revealed a 10-bp deletion in exon 8 leading to a premature stop codon in
exon 9
Table 1 Characteristics of the families analysed for PTEN mutations
Number of Number of BRCA1 Mutation BRCA2 Mutation
cases per family families analysis analysis
Breast cancer only 1* 2 All neg. All neg. for f.m.
2 4 All neg. All neg. for f.m.
3 7 All neg. 3 fam. neg.
1 fam. neg. for f.m.
³4 6 All neg. 2 fam. neg.
Breast and ovarian cancer 3 1 All neg. All neg. for f.m.
³4 5 All neg. 2 fam. neg. for f.m.
Clinical characteristics of the analysed families (fam.) at risk for breast and/or ovarian cancer. *In the two families with one case of breast cancer only, ages at
manifestation were 33 and 34 years. All families were negative (neg.) for BRCA1 mutations. BRCA2 mutations could be excluded in five families. Additionally,
ten families were tested negative for frequent BRCA2 mutations (f.m.) in the exons 9, 23 and 27.756 D Freihoff et al
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Hoefer, San Francisco, USA) using 10% acrylamide gels with a
bisacrylamide:acrylamide ratio of 1:59 or 12% acrylamide gels
with a bisacrylamide:acrylamide ratio of 1:29 and 1:79, electro-
phoresis at 5–10 W and variable temperatures for 14 h. Silver
staining of the gels was performed as previously described (von
Deimling et al, 1993; Bender et al, 1994). Aberrantly migrating
SSCP bands were excised and the DNA was extracted. After ream-
plification with the same set of primers, the PCR products were
sequenced on a semiautomated sequencer (Applied Biosystems,
model 310, Foster City, USA) using a Taq cycle sequencing kit
(Abi Prism) dye terminator cycle sequencing ready reaction kit,
Perkin Elmer, Alameda, USA).
Under the same conditions used here, we previously detected 32
mutations in brain tumours (Duerr et al, 1998). These mutations
included deletions, insertions, missense and nonsense mutations in
exons 1–8.
Analysis for homozygous deletions
A PCR assay for the detection of homozygous deletions has been
described previously (Hayashi et al, 1997). In brief, a 160-bp frag-
ment including exon 4 of the PTEN gene was coamplified with a
171-bp fragment from intron 7 of the DESMIN (DES, chromosome
2) gene as a control (Duerr et al, 1998). One primer of each pair
was labelled with infrared dye 41 (MWG-Biotech, Ebersberg,
Germany) at the 5¢ end. Differential PCR was performed in a final
volume of 10 ml containing 10 ng DNA, 50 mM potassium chlo-
ride, 1.5 mM magnesium chloride, 10 mM tris-HCl, pH 8.3, 200 mM
of each dNTP, 0.1% gelatin, 5 pmol of each primer, and 0.25 U
Taq polymerase (Gibco-BRL). Initial denaturation at 94°C for
3 min, was followed by 28 cycles on an automated thermocycler
(Hybaid, Omnigene). These included denaturation at 94°C for
40 s, annealing at 56°C for 55 s and extension at 72°C for 55 s. A
final extension step of 10 min at 72°C was used. Fluorescent PCR
products were separated on a 6% polyacrylamide gel and analysed
on a semiautomated DNA sequencer (Licor, Lincoln, NE, USA).
Quantitative analysis of the signal intensity was carried out with
the One-Dscan program (Scanalytics). To determine the
PTEN/DES ratios in normal DNA samples, leucocyte DNA from
40 healthy controls and patients was analysed. PTEN:DES ratios
ranged from 1.5 to 3.2, averaging 2.2 with a standard deviation
(s.d.) of 0.41. PTEN:DES ratios lower than mean minus 3 s.d., i.e.
<0.97, were considered as indicative of PTEN deletions. DNA of
the glioblastoma cell line A172 lacking the Cowden critical region
was used as a positive control (Li et al, 1997).
Detection of allelic imbalance
Three microsatellite markers D10S573, D10S215 and D10S564
located on chromosomal band 10q23.1–23.3 were used for the
detection of allelic loss in the PTEN genomic region. With these
same markers, linkage analysis provided highest lod scores in
Cowden disease families and the Cowden locus was mapped
between markers D10S215 and D10S564 (Nelen et al, 1997).
Eighty of these tumours were also analysed for allelic loss in the
regions of the BRCA1, BRCA2 and TP53 genes and 16q24 using the
microsatellite markers D17S855, D13S267, TP53 and D16S539.
Two dinucleotide repeats (D2S136 and D5S346) and two
mononucleotide repeats (BAT25 and BAT26) previously identified
as frequent targets for microsatellite instability in hereditary non-
polyposis colon carcinoma (HNPCC) were examined in a panel of
11 carcinomas (Bocker et al, 1997).
Genomic DNA (100 ng) from tumours and corresponding
leucocytes was used as template. PCR was performed in a volume
of 10 ml containing 20 ng of DNA, 50 mM potassium chloride,
10 mM tris-HCl, 200 mM of each dNTP, 0.1% gelatin, 10 pmol of
each primer, 1.5 mM magnesium chloride and 0.025 U Taq poly-
merase. Initial denaturation at 94°C for 3 min was followed by 32
cycles on an automated thermal cycler (Bio-med 623, Theres,
Germany). These included denaturation at 94°C for 50 s,
annealing at 53°C (D10S215), 57°C (D10S564) and 59°C
(D10S573) for 50 s and extension at 72°C for 40 s. A final exten-
sion step at 72°C for 10 min was added. Loss of heterozygosity
analysis was performed on a sequencing apparatus (Pokerface II,
Hoefer) using denaturating 8% acrylamide gels with a bisacry-
lamide:acrylamide ratio of 1:19 and electrophoresis at 75 W for
2.5 h. Silver staining of the gels was carried out as previously
described (von Deimling et al, 1993; Bender et al, 1994).
RESULTS
Mutation detection by SSCP and direct sequencing
The index patients of the 25 breast cancer families were examined
for germline mutations in PTEN. BRCA1 mutations had previously
been excluded. Five families were negative for BRCA2 mutations
and an additional ten families were negative for frequent mutations
in exons 9, 23 and 27. No abberant migration patterns of the PTEN
SSCP fragments could be detected in any of these patients.
One of the 103 sporadic tumours showed an altered migration
pattern. Sequence analysis revealed a 10-bp deletion within exon 8
resulting in a truncated protein with a stop signal at codon 343 in
exon 9. This mutation was proven to be of somatic origin by
analysis of constitutional DNA (Figure 1). No LOH could be
observed in this tumour sample for the other allele. The tumour
occurred in a 67-year-old woman and was histopathologically
classified as an invasive ductal carcinoma, pT1c, pN0, pM0, WHO
grade III, oestrogen and progesterone positive.
Homozygous deletions
Our tumour samples were also screened for homozygous deletions.
Carcinoma samples with PTEN:DES ratios lower than mean minus
3 s.d., i.e. <0.97, were considered to have PTEN deletions in order
to introduce a correction factor for the contamination of breast
carcinoma tissue with stromal cells. Applying this calculation, none
of the tumours showed evidence for a homozygous deletion of the
PTEN gene (Figure 2).
TTT C
DES
PTEN
Figure 2 Analysis of homozygous deletions in sporadic breast carcinomas.
Genomic DNA samples of breast carcinomas (T) were amplified by PCR
using intronic primers. DNA from the glioblastoma cell line A172 served as
positive control (C). A 160-bp fragment including exon 4 of the PTEN gene
was coamplified with a 171-bp fragment from intron 7 of the DESMIN gene.
Bands were detected by the semiautomatic sequencer Licor 4200 and
analysed with the One-Dscan-Software. Significant differences between
DESMIN and PTEN signal intensity were only observed for the DNA template
of the glioblastoma cell linePTEN mutations in breast cancer 757
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Loss of heterozygosity
Analysis of three microsatellite markers in 92 informative carci-
nomas revealed ten tumours with LOH10q in at least one locus.
However, only two carcinomas exhibited LOH including the entire
Cowden critical region (Figure 3).
LOH analysis in other chromosomal regions revealed frequen-
cies of 20% for the marker D17S855 (16 out of 79 informative
tumours), 20% for the marker D13S267 (13 out of 68), 41% for the
marker TP53 (13 out of 32) and 60% for the marker D16S539 (30
out of 51).
Microsatellite instability
To examine a potential association of PTEN mutations with
microsatellite instability, four microsatellite markers located on
different chromosomes were analysed in a panel of 11 carcinomas
including ten carcinomas without PTEN mutations and the one
tumour with a PTEN mutation. No evidence for microsatellite
instability was observed with any of these markers.
DISCUSSION
Recent reports on mutations of the PTEN tumour-suppressor gene
in Cowden disease and in a variety of different tumour entities
have raised the possibility of an involvement of PTEN in breast
carcinogenesis (Li et al, 1997; Liaw et al, 1997; Steck et al, 1997).
We here present data of a PTEN mutational analysis in 103
sporadic breast carcinomas and 25 families afflicted with heredi-
tary breast and ovarian cancer. The results strongly indicate that
alterations of the PTEN gene are a rare event in breast carcinomas.
Analysis of PTEN in Cowden syndrome and early onset familial
breast cancer also failed to detect germline mutations in this subset
of breast cancer families (Tsou et al, 1997). Moreover, the authors
of a recent report failed to detect any germline mutation in the
PTEN gene in a set of 136 breast cancer families in which alter-
ations of BRCA1, BRCA2, TP53 and ATM were previously
excluded (Chen et al, 1998). Our analysis comprised families with
breast and/or ovarian cancer not restricted to early onset of the
disease. The absence of germline mutations in both studies implies
that PTEN does not contribute significantly to the formation of
hereditary breast and ovarian cancer. Rhei et al (1997) described a
somatic 2-bp deletion and a 4-bp germline deletion in a series of
54 unselected primary breast cancers. Subsequent clinical exami-
nation attributed the germline deletion to a family history of
Cowden syndrome. Ueda et al (1998) detected only one missense
mutation in a series of 69 primary breast cancers. These data are in
accordance with our results demonstrating that PTEN mutations
are an infrequent event in primary sporadic breast cancer.
Moreover, in contrast to initial results on breast cancer cell lines
(Li et al, 1997), our findings indicate that homozygous deletions
are uncommon in primary breast carcinomas.
In addition to the two mutations, Rhei et al (1997) identified
several missense variants that occurred in most of the tumour
samples. Recently, a highly conserved and processed PTEN
pseudogene has been found on chromosomal band 9p21
(Bostroem et al, 1998; Dahia et al, 1998). This gene shares 98%
sequence homology with the coding region of functional PTEN.
Analysis of cDNA from a glioblastoma cell line with PTEN dele-
tion suggests that the pseudogene is transcriptionally inactive.
Nine of the 11 variants described by Rhei et al (1997) align with
the pseudogene sequence. As this analysis was performed with a
cDNA template, any of the mRNA variants may well represent
a DNA pseudogene contamination of the mRNA samples.
Alternatively, the pseudogene may be expressed in breast carci-
noma. However, in our analysis of genomic DNA from 103
primary tumours, we could not detect any sequence variation.
The association of PTEN mutations in microsatellite instability-
positive endometrial carcinomas (Tashiro et al, 1997) raised the
possibility that PTEN may be associated with microsatellite
instability. This property is also supported by the detection of
microsatellite instability on chromosomal band 10q11–qter in
primary breast carcinomas (Sourvinos et al, 1997). It was, there-
fore, of interest to analyse these tumours for microsatellite insta-
bility. However, our analysis with four microsatellite markers that
represent frequent targets of replication error did not reveal
microsatellite instability neither in the tumour sample exhibiting a
PTEN mutation nor in ten breast carcinomas without mutant PTEN.
In contrast to the initial reports of high allelic loss rates in the
PTEN region on chromosome 10q in 50% and 34% of primary
breast carcinomas respectively (Li et al, 1997; Steck et al, 1997),
our analysis revealed LOH10q23 in less than 10% of the tumours.
No allelic loss was detected in the carcinoma carrying a PTEN
mutation. This is in agreement with the observation of
Kerangueven et al (1997), who also failed to identify a significant
incidence of LOH10q in a panel of 115 breast carcinomas.
However, the investigators of a recent report (Singh et al, 1998)
could detect loss of heterozygosity close to the PTEN region in 9
out of 22 breast carcinomas. LOH10q23 in these tumour samples
was associated with high-grade tumours. This is in accordance
with Rasheed et al (1997), who suggested that in gliomas PTEN
mutations are restricted to high-grade tumours. The low frequency
of LOH10q23 in our tumour panel may be explained by the
predominance of early stage tumours with a favourable prognosis.
This is supported by the detection of significant LOH frequencies
of 20–60% in other chromosomal regions frequently altered in
early stage breast carcinomas.
In addition, we could not detect homozygous PTEN deletions in
our primary breast carcinoma samples as reported by other groups
(Li et al, 1997; Steck et al, 1997). To detect focal homozygous
deletion, we have chosen to amplify exon 4 because the minimal
region of loss occurred between exons 2 and 5 in tumour cell lines
(Steck et al, 1997). It is, therefore, unlikely that we have missed a
significant portion of homozygous deletions.
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Figure 3 LOH analysis of markers closely spaced to the Cowden critical
region. In 10 of 92 informative carcinomas, LOH was observed in at least one
marker, but in only two tumours (no. 7 and no. 10) the Cowden critical region
was flanked by LOH758 D Freihoff et al
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In summary, our findings suggest that PTEN does not play a
major role in the pathogenesis of sporadic and hereditary breast
cancer. It remains to be studied whether another, yet unidentified,
tumour-suppressor gene on chromosome 10q participates in
mammary carcinogenesis.
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